Anti-hepatic fibrotic effect by interferon free therapy for patients with chronic liver disease type C

Anti-hepatic fibrotic effect by interferon free therapy for patients with chronic liver disease type C - IFN free B study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015806

Enrollment

100

Registered

2020-12-31

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic liver disease type C

Interventions

Daclatasvir/Asunaprevir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with genotype 1b HCV, chronic liver disease. IFN null responder or IFN ineligible or intolerant

Exclusion criteria

Exclusion criteria: Liver cancer, Non-compensated hepatic cirrhosis, HIV, Pregnant women

Design outcomes

Primary

Measure	Time frame
Improvement of hepatic fibrosis	—

Secondary

Measure	Time frame
Sustained viral response	—

Countries

Japan

Contacts

Public ContactAkihiro Tamori

Osaka City University Graduate School of Medicine Department of Hepatology

atamori@med.osaka-cu.ac.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026